“Establishing our global pharmaceutical headquarters in New Jersey opens up opportunities to partner with other pharmaceutical companies and to drive commercialization of new products,” said Gerald Ostrov, B&L’s chief executive officer.
“Our recently announced co-promotion agreement with Pfizer for prescription ophthalmics in the U.S. is the first example of how we are successfully implementing this strategy.”
In addition to the new 30,000 sq.ft. facility here, B&L maintains its worldwide headquarters in Rochester, N.Y., and has research and development facilities around the globe.
The new pharmaceutical headquarters will house that division’s global and U.S. leadership as well as its sales and marketing teams, according to Flemming Ornskov, global president of B&L’s pharmaceutical business. ■
